|$AEMD 06-18-2020 Aethlon Announces FDA Approval of IDE||mick||08/25/20 12:35 AM|
|AEMD Aethlon Medical Inc||mick||02/05/23 7:45 PM|
|I tried to tell you that. I||uber darthium||02/04/23 1:12 PM|
|yes, something not right Aethlon Medical Inc||mick||02/04/23 12:30 PM|
|Somehow I knew you would still be here||uber darthium||02/03/23 10:10 PM|
|plus they have plenty of cash and relatively||Monroe1||02/03/23 5:37 PM|
|I'm a hold also. I'm looking||chiefs1||02/03/23 3:17 PM|
|was a good presentation. no doubt about the||
|Monroe1||02/03/23 1:33 PM|
|Did anyone watch the presentation today.||chiefs1||02/02/23 5:10 PM|
|The corruption at the FDA and CDC/NIH is||Monroe1||12/20/22 10:22 AM|
|AEMD Aethlon Medical Inc||mick||12/18/22 6:29 PM|
|unchanged AEMD||mick||11/14/22 6:38 PM|
|We'll see after hours, AEMD reports @ 4:15||Nukemtiltheyglow||11/14/22 10:33 AM|
|me too , lot to be had here $AEMD||mick||11/13/22 2:23 PM|
|I own Aethlon, bought near the high. :D(||Nukemtiltheyglow||11/13/22 1:50 PM|
|AEMD Aethlon Medical Inc||mick||10/24/22 12:46 PM|
|wow read M1||mick||10/24/22 12:46 PM|
|too cheap, so i bot a few. Any||Monroe1||10/24/22 12:23 PM|
|AEMD Aethlon Medical Inc||mick||10/23/22 2:15 PM|
|unreal pps share $Aethlon med||mick||10/23/22 2:15 PM|
|AEMD Aethlon Medical Inc||mick||08/31/22 7:17 PM|
|yes, way back in the late eighties or||Monroe1||08/16/22 11:15 AM|
|THANKS, 'C-11", Dude!!!||Invest-in-America||08/12/22 1:12 PM|
|2 groups gave Aethlon medical a "buy" rating||chiefs11||08/11/22 8:35 PM|
|I HEAR ya, Dude! And the CRICKETS, too!||Invest-in-America||08/11/22 12:18 PM|
|The good news is the 23 million they've||chiefs11||08/11/22 12:08 PM|
|Well it looks like we're back to crickets lol...||chiefs11||08/11/22 12:04 PM|
|AEMD: Already SOARING back UP 'After Hours', SUCKAS !!!!||Invest-in-America||08/03/22 4:28 PM|
|AEMD: To keep this 'Politically- CORRECT ', I SHOUL||Invest-in-America||08/03/22 4:18 PM|
|AEMD: Gimmmy-dooose-cheeeeepies, SUCKAS!!!!!||Invest-in-America||08/03/22 3:52 PM|
|AEMD: I wouldn't give-up behind THIS little puppy||Invest-in-America||08/03/22 2:04 PM|
|AEMD: If we can get the MMs, Flippers,||Invest-in-America||08/03/22 12:21 PM|
|AEMD: Hope so!! (As the REST of all||Invest-in-America||08/03/22 11:14 AM|
|looks like she is running now.||gail||08/03/22 10:52 AM|
|AEMD: Well, HI Gail!! I'm in this one||Invest-in-America||08/03/22 10:50 AM|
|newbie to the AEMD board. I bought in||Nukemtiltheyglow||08/03/22 10:13 AM|
|wow, I …….||gail||08/02/22 9:26 PM|
|Large pop AH's all of a sudden MPV||$$ Golden Cross $$||08/02/22 6:30 PM|
|Nice pop in AH! Glad I bought today.||Tim696969||08/02/22 6:20 PM|
|Going now weeee||europtiger||08/02/22 6:16 PM|
|grabbed a few here, hi all.||gail||08/02/22 3:59 PM|
|Pelosi landing @ 10:20e in Taiwan. China promising||S3lfMade||08/02/22 7:55 AM|
|Pre-market trading is heavy. Last check $1.47||subslover||08/02/22 7:30 AM|
|AEMD yes||mick||08/01/22 10:07 PM|
|Decent AH spike. Also check out||Monkmojo||08/01/22 9:22 PM|
|yes $aemd||mick||08/01/22 2:31 PM|
|Yep, holding gains well||$$ Golden Cross $$||08/01/22 2:13 PM|
|$AEMD will be the best performing monkeypox stock||mick||08/01/22 2:12 PM|
|Is 30 million shares authorized.. 62 million shares||chiefs11||08/01/22 2:12 PM|
|finally!||Monroe1||08/01/22 11:45 AM|
|Yes, Sir||$$ Golden Cross $$||08/01/22 9:38 AM|
At Aethlon Medical, we are a leading developer of immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's natural immune defenses,
the Aethlon Hemopurifier® eliminates life-threatening disease targets that are often shielded from the immune system and not well addressed by traditional drug therapies.
The technology captures circulating viruses, bacterial toxins and cancer promoting exosomes through affinity attachment to a unique structure cloaks these targets from immune detection.
At present, the Hemopurifier® is being advanced under an FDA approved clinical study. Aethlon is also the majority owner of Exosome Sciences, Inc.,
a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases.
Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical,
is focused on the discovery of exosomal biomarker candidates to diagnose and monitor life-threatening diseases.
The proprietary Enzyme-Linked Lectin-Specific Assay (ELLSA™) serves as a platform to isolate exosomal biomarkers from a wide-range of bodily fluids.
In preliminary studies, ELLSA™ demonstrated the ability to isolate exosomes from urine, which resulted in high-sensitivity detection of HIV-infection.
Specific to neurological disorders, Exosome Sciences discovered TauSome™, an exosomal biomarker that may be the first non-invasive candidate to
detect Chronic Traumatic Encephalopathy (CTE) in living individuals. In a study of former National Football League (NFL) players,
TauSome levels were found to be significantly higher as compared to athlete control subjects who participated in non-contact sports.
TauSome levels also correlated with cognitive decline based standardized tests of memory and psychomotor speed. Visit www.exosomesciences.com for additional details.
Time Magazine named the Hemopurifier® a "Top 25 Invention" and a "Remarkable Advance in Healthcare" based on its use in treating Ebola virus.
Emerging pathogens pose a significant threat to mankind. Of the hundreds of viral pathogens known to be infectious to man, only a few are addressed with
proven antiviral drug or vaccine therapies. Beyond the looming threat of bioterrorism, a proliferation of international travel, urban crowding and global warming
is expected to accelerate the emergence of future pandemics. In response, the U.S. Department of Health and Human Services (HHS) has established an initiative
to support platform technology medical countermeasures with broad-spectrum capabilities. Based on preclinical studies and human treatment experiences, the Aethlon Hemopurifier® defines this initiative.
To date, Hemopurifier therapy has been administered to individuals infected with Ebola virus, Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV).
In the case of Ebola, a remarkable response to a single administration of Hemopurifier therapy (comatose physician with multiple organ failure at the time), led to
Time Magazine naming the Hemopurifier to be one of the "Top 25 Inventions" as well as one of the "Eleven Most Remarkable Advances in Healthcare."
Beyond human treatment experiences, pre-clinical Hemopurifier studies have validated the broad-spectrum capture of numerous viral threats.
These include: Chikungunya, Dengue and West Nile virus, as well as Vaccinia and Monkey pox, which serve as models for human Smallpox infection.
Specific to pandemic influenza threats, Aethlon has validated the capture of H5N1 avian flu, H1N1 swine flu, and the reconstructed 1918 influenza virus,
which represents a model for the strain of influenza that killed an estimated 50 million victims in 1918 and 1919. In vitro studies of other viral threats are ongoing.
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.